These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24060578)

  • 1. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
    Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J
    Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
    Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
    Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
    J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
    Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
    BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
    Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
    J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
    Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer.
    Zhang M; Liu HX; Teng XD; Wang HB; Cui J; Jia SS; Gu XY; Li ZG
    Ultrastruct Pathol; 2012 Dec; 36(6):381-6. PubMed ID: 23216236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
    Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
    Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subset of breast cancer predisposes to brain metastasis.
    Shao MM; Liu J; Vong JS; Niu Y; Germin B; Tang P; Chan AW; Lui PC; Law BK; Tan PH; Tse GM
    Med Mol Morphol; 2011 Mar; 44(1):15-20. PubMed ID: 21424932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].
    Joubert C; Boissonneau S; Fina F; Figarella-Branger D; Ouafik L; Fuentes S; Dufour H; Gonçalves A; Charaffe-Jauffret E; Metellus P
    Neurochirurgie; 2016 Jun; 62(3):151-6. PubMed ID: 27236733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
    Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
    Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.